Morgan Stykel
Senior Scientist Aquinnah Pharmaceuticals
Seminars
Thursday 5th February 2026
Leveraging Proteomics for Target Identification & Mechanistic Insights in Pre-Clinical Drug Discovery
3:45 pm
- Use of limited proteolysis to identify candidate target proteins for Aquinnah Pharmaceuticals’ small molecule aimed at reducing tau pathology
- Confirmation of target using siRNA screening using in-house phenotypic assays
- Ongoing proteomic studies to define how the compound modulates target activity and its broader biological impact
